Reuters: Regulatory News: Bayer seeks approval for Xarelto in lung embolism

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Bayer seeks approval for Xarelto in lung embolism Apr 12th 2012, 06:56 FRANKFURT, April 12 | Thu Apr 12, 2012 2:56am EDT FRANKFURT, April 12 (Reuters) - German drugmaker Bayer said it submitted its Xarelto blood-thinning pill for European Union approval for the treatment of dangerous blood clots of the lung, a condition known as pulmonary embolism. It also applied for approval for the pill's use in preventing recurrent deep vein thrombosis - another form of blood clotting - it said in a statement on Thursday. Bayer and its development partner Johnson & Johnson's said last month blood clot preventer Xarelto proved as effective as and safer than standard treatments pulmonary embolism in a big study. This could possibly pave the way for it to become the eventual preferred treatment for the third most common cause of deaths in hospitals.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions